Format

Send to

Choose Destination
Rev Mal Respir. 2017 May;34(5):576-580. doi: 10.1016/j.rmr.2016.08.002. Epub 2016 Sep 17.

[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].

[Article in French]

Author information

1
Service de pneumologie, centre hopspitalier intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France. Electronic address: julien.caliez@gmail.com.
2
Service de pneumologie, centre hopspitalier intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.
3
Service d'anatomopathologie et de biologie moléculaire, hôpital Henri-Mondor, 94000 Créteil, France.

Abstract

INTRODUCTION:

Among patients with non-small-cell lung cancer, coexistence of EGFR mutation and ALK rearrangement is rare. We describe the clinical features of two patients with this double anomaly.

CASE REPORTS:

A 62-year-old Caucasian non-smoking woman was diagnosed with cT4N0M0 lung adenocarcinoma. Initial biopsy showed EGFR mutation and ALK rearrangement. She received cisplatin-gemcitabine, followed by 17 months of gemcitabine. Owing to progression, she received erlotinib for 14 months, then paclitaxel for 6 months and finally crizotinib. A partial response was achieved and maintained for 24 months. A 45-year-old Caucasian woman, light smoker, was diagnosed with cT2N3M0 lung adenocarcinoma. Only EGFR mutation was found on initial analysis. She underwent treatment with cisplatin-gemcitabine and thoracic radiotherapy. Progression occurred after 8 months and afatinbib was started. Eight months later, progression was observed with a neoplasic pleural effusion in which tumor cells expressing ALK rearrangement were found. A new FISH analysis was performed on the initial tumor but did not find this rearrangement. Despite a third line of crizotinib, the patient died one month later.

DISCUSSION:

The literature shows 45 other cases of these two abnormalities, observed either from the start or during follow-up. EGFR's TKI were almost always given before ALK's TKI.

CONCLUSIONS:

Therapeutic strategy needs to be clarified in cases of double alteration. With regard to the second patient, appearance of ALK rearrangement may constitute a resistance mechanism to EGFR's TKI.

KEYWORDS:

Anaplastic lymphoma kinase translocation; Biologie moléculaire; Cancer bronchique non à petites cellules; EGFR mutation; Molecular biology; Mutation de l’EGFR; Non-small-cell lung carcinoma; Translocation ALK

PMID:
27646667
DOI:
10.1016/j.rmr.2016.08.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Masson (France)
Loading ...
Support Center